

PlsX and PlsY

Additional roles beyond glycerophospholipid synthesis in Gram-negative bacteria

Rex, Audrey N.; Simpson, Brent W.; Bokinsky, Gregory; Trent, M. Stephen

DOI

[10.1128/mbio.02969-24](https://doi.org/10.1128/mbio.02969-24)

Publication date

2024

Document Version

Final published version

Published in

mBio

Citation (APA)

Rex, A. N., Simpson, B. W., Bokinsky, G., & Trent, M. S. (2024). PlsX and PlsY: Additional roles beyond glycerophospholipid synthesis in Gram-negative bacteria. *mBio*, 15(12). <https://doi.org/10.1128/mbio.02969-24>

Important note

To cite this publication, please use the final published version (if applicable). Please check the document version above.

Copyright

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy

Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim.

PlsX and PlsY: Additional roles beyond glycerophospholipid synthesis in Gram-negative bacteria

Audrey N. Rex,¹ Brent W. Simpson,² Gregory Bokinsky,³ M. Stephen Trent^{1,2}

AUTHOR AFFILIATIONS See affiliation list on p. 15.

ABSTRACT The unique asymmetry of the Gram-negative outer membrane, with glycerophospholipids (GPLs) in the inner leaflet and lipopolysaccharide (LPS) in the outer leaflet, works to resist external stressors and prevent the entry of toxic compounds. Thus, GPL and LPS synthesis must be tightly controlled to maintain the integrity of this essential structure. We sought to decipher why organisms like *Escherichia coli* possess two redundant pathways—PlsB and PlsX/Y—for synthesis of the GPL precursor lysophosphatidic acid (LPA). LPA is then converted by PlsC to the universal precursor for GPL synthesis, phosphatidic acid (PA). PlsB and PlsC are essential in *E. coli*, indicating they serve as the major pathway for PA synthesis. While loss of PlsX or PlsY individually has little consequence on the cell, the absence of both was lethal. To understand the synthetic lethality of this seemingly redundant PlsX/Y pathway, we performed a suppressor screen. Suppressor analysis indicated that $\Delta plsXY$ requires increased levels of glycerol-3-phosphate (G3P), a GPL precursor. In agreement, $\Delta plsXY$ required supplementation with G3P for survival. Furthermore, loss of PlsX dysregulated fatty acid synthesis, resulting in increased long-chain fatty acids. We show that although PlsX/Y together contribute to PA synthesis, they also contribute to the regulation of overall membrane biogenesis. Thus, synthetic lethality of $\Delta plsXY$ is multifactorial, suggesting that PlsX/Y has been maintained as a redundant system to fine-tune the synthesis of major lipids and promote cell envelope homeostasis.

IMPORTANCE Gram-negative bacteria must maintain optimal ratios of glycerophospholipids and lipopolysaccharide within the cell envelope for viability. Maintenance of proper outer membrane asymmetry allows for resistance to toxins and antibiotics. Here, we describe additional roles of PlsX and PlsY in *Escherichia coli* beyond lysophosphatidic acid synthesis, a key precursor of all glycerophospholipids. These findings suggest that PlsX and PlsY also play a larger role in impacting homeostasis of lipid synthesis.

KEYWORDS PlsX, PlsY, PlsB, glycerophospholipids, phospholipids, phosphatidic acid, Gram-negative bacteria

The bacterial cell envelope has a complex composition that serves to provide protection from various environmental stresses while allowing for influx of nutrients (1). Gram-positive bacteria are monoderms with a single lipid bilayer and thick peptidoglycan cell wall. In contrast, Gram-negative bacteria are diderms with two lipid bilayers encasing a thin layer of peptidoglycan. The Gram-negative inner membrane is symmetric with both leaflets composed of glycerophospholipids (GPLs). The outer membrane (OM), however, is asymmetric with the inner leaflet consisting of GPLs and the outer leaflet containing the glycolipid lipopolysaccharide (LPS) (2, 3). Asymmetry of the OM provides a robust barrier to protect the cell from toxic molecules and antibiotics, given that proper lipid composition is maintained. Currently, antibiotic resistance represents a major global health crisis as bacteria have evolved resistance to a broad range of treatments (4).

Editor Nina R. Salama, Fred Hutchinson Cancer Center, Seattle, Washington, USA

Address correspondence to M. Stephen Trent, strent@uga.edu.

The authors declare no conflict of interest.

See the funding table on p. 15.

Received 25 September 2024

Accepted 3 October 2024

Published 30 October 2024

Copyright © 2024 Rex et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Furthermore, the unique properties of the Gram-negative cell envelope make these organisms naturally resistant to many antibiotics that are otherwise effective against Gram-positive bacteria. Thus, understanding assembly and maintenance of the OM is crucial for developing targeted antimicrobial treatments.

The universal precursor for GPL synthesis is phosphatidic acid (PA), which is enzymatically synthesized through a two-step acylation of glycerol-3-phosphate (G3P) (5–9). Bacteria may contain two separate enzymes for the first acylation step of G3P. PlsB (G3P 1-*O*-acyltransferase) synthesizes lysophosphatidic acid (LPA), utilizing either acyl-acyl carrier protein (ACP) or acyl-coenzyme A (CoA) as the fatty acyl donor (Fig. 1A). Alternatively, LPA can be generated by PlsY (G3P 1-*O*-acyltransferase) which requires an acyl-phosphate (PO₄) as a specialized acyl donor. The latter is synthesized by PlsX through the conversion of acyl-ACP to acyl-PO₄. Next, PlsC (LPA 2-*O*-acyltransferase) adds an additional acyl chain to LPA and, like PlsB, can utilize acyl-ACP and/or acyl-CoA (8, 9) (Fig. 1A). Although discovered after PlsB, the most widespread mechanism for the first acylation reaction and generation of LPA is through PlsX/Y. In fact, most Gram-negative proteobacteria, especially occurring in γ -proteobacteria like *E. coli*, maintain both systems—PlsX/Y and PlsB—for the initiation of PA synthesis (10). It should be noted that the only bacterial species known to maintain only PlsB/C is Xanthomonadales, a subset of γ -proteobacteria (8).

In species with only one route for PA synthesis, either through PlsB/C or PlsX/Y/C, each enzyme is essential for growth. Therefore, in *E. coli* it would be expected that PlsB, PlsX, or PlsY would not be essential due to redundancy within this pathway. However, *plsX* and *plsY* single mutants are viable while PlsB is essential; these results suggest that PlsB activity is the major enzymatic route for the generation of LPA for GPL synthesis (11). Surprisingly, loss of both PlsX and PlsY is synthetically lethal in *E. coli* (12). Since the enzymatic function of PlsY is directly dependent upon a donor generated by PlsX and the fact that single *plsX* and *plsY* mutants are viable yet the double mutant is not, it suggests that PlsX and PlsY have an additional role outside of the traditional synthetic pathway.

Here, we sought to dissect the roles of PlsX and PlsY in γ -proteobacteria by selecting for suppressors of the synthetic lethal phenotype of a *plsXY* double mutant. Characterization of suppressor mutations suggested that $\Delta plsXY$ had insufficient precursors to support GPL synthesis. We found that loss of PlsX results in an increased concentration of very long-chain (C18:0/1-C20:0/1) acyl-ACPs. Long-chain acyl-ACPs are sensed by the cell to decrease initiation of fatty acid synthesis (FASII in *E. coli*) (13), which was likely part of the toxicity from loss of PlsX and PlsY. These data suggested that PlsX had a regulatory role in balancing GPL precursors. In agreement, slowing down FASII through chemical treatment was toxic to $\Delta plsY$, mimicking the synthetic lethality of the *plsXY* mutant. Together, our data suggest that the combination of reduced PA flux, imbalance of GPL precursors caused by the loss of PlsX, and a tertiary role of PlsY results in synthetic lethality of $\Delta plsXY$.

RESULTS

Loss of both PlsX and PlsY is synthetically lethal

PA is the universal precursor for GPL synthesis. *E. coli* and other proteobacteria have evolved to maintain two mechanisms for the first step of PA synthesis: PlsB, which is essential, and PlsX and PlsY, which are not individually essential (Fig. 1A). In 2007, synthetic lethality of a *plsXY* double mutant was suggested by the inability to generate colonies via phage transduction (12). However, this method is not the most robust way to prove synthetic lethality. In this new era of sequencing, we can quickly, accurately, and affordably identify suppressors across the genome of an entire strain, so we sought first to validate this synthetic lethality and to then select for suppressors. As expected, in single mutants lacking *plsX* or *plsY*, there was no apparent growth defect (Fig. S1). Next, we introduced a $\Delta plsY::kan$ allele into the *plsX* mutant while expressing *plsX* *in trans* from an arabinose-inducible promoter. These cells were grown under inducing (+ arabinose)




FIG 1 Loss of PlsX and PlsY results in a synthetically sick strain. (A) *Escherichia coli* synthesizes PA via a two-step acylation of G3P. G3P substrate is generated either via TpiA/GpsA, first generating dihydroxyacetone (DHAP) from glyceraldehyde-3-phosphate (GAP) before conversion to G3P, or through *de-novo* synthesis via GlpK. G3P can be reversed to DHAP via GlpD. DHAP can be shunted irreversibly to methyl-glyoxal, a toxic compound, via MgsA (green inset). Fatty Acid Synthesis (FASII) generates acyl-ACP of appropriate carbon lengths to serve as acyl donors (gray inset). The first acylation of G3P is catalyzed by either PlsB or PlsY, enzymes that produce LPA. The second acylation step generates PA via the universally conserved protein, PlsC. PlsB and PlsC use both acyl-ACP and acyl-CoA as donor substrates, whereas PlsY can only use an acyl-PO₄ that is specifically generated by PlsX. PA is immediately used in GPL biosynthesis. (B) Depletion growth curve showing a synthetic growth defect of $\Delta plsX \Delta plsY$. Strains were grown in lysogeny broth (LB) amp under inducing (0.05% arabinose) or repressing (0.05% glucose) conditions. Two back-dilutions (denoted by arrows) were performed at three and five hours to sufficiently deplete PlsX. Error bars represent standard deviation (SD) from three biological replicates and are not shown if smaller than the symbols.

conditions overnight, washed, and switched to repressing (+ glucose) conditions. As expected, the *plsXY* double mutant displayed a severe synthetic growth defect after two dilutions to sufficiently deplete PlsX levels, supporting synthetic lethality (Fig. 1B).

To fully demonstrate that $\Delta plsXY$ is synthetically lethal, we performed co-transduction using P1 phage raised on $\Delta plsY$ also containing a kanamycin resistance cassette in *ygjH* ($\Delta ygjH::kan$), a gene closely linked to *plsY*. Following P1 transduction into a $\Delta plsX$ recipient strain, bacteria were selected on kanamycin and screened for both gene deletion, via primers that anneal to regions flanking *plsY*, and gene duplication, via primers that anneal to regions within *plsY*. We obtained an experimental co-transduction frequency of 51.3% into our wild-type (WT) strain, W3110. The co-transduction frequency between $\Delta ygjH::kan$ and $\Delta plsY$ was disrupted when brought into $\Delta plsX$ recipient strain with 0% containing the deletion of *plsY* (Table S1). We also tested to see if gene deletion order mattered and found via co-transduction frequencies that it does not (Table S1). Together, these results conclusively demonstrate synthetic lethality of a *plsXY* double mutant, regardless of gene deletion order.

It should be noted that *plsX* is in an operon with essential fatty acid synthesis genes. We conducted RNA-sequencing (RNA-seq) to determine if there were any polar effects

on *fabH*, *fabD*, and *fabG* gene expression, as well as to probe for possible dysregulation of other genes outside of this operon. In a Δ *plsX* background, the only changes in gene expression of statistical significance (fold change >2, false discovery rate (FDR) *P*-value ≤ 0.05) were *plsX* transcripts, which were absent due to the gene deletion (-504 -fold change, $4.48E-43$ FDR *P*-value), and *cspG* (cold shock protein) transcripts (-3.18 -fold change, 0.02 FDR *P*-value; Data Set S1). There was no evidence of polar effects on *fabH*, *fabD*, and *fabG* in Δ *plsX* in our working conditions.

Isolation of suppressor mutations that rescue Δ *plsXY* synthetic lethality

To identify genes that overcome the synthetic lethal phenotype, we isolated suppressors via large-scale transduction as described previously (14), with the Δ *plsX::kan* allele into a *plsX* recipient strain and vice versa (Δ *plsX::kan* allele into a *plsY* recipient strain). Suppressors arose within 16 hours, were isolated, and mutations were identified by whole-genome sequencing (WGS). Mutations arose frequently in the genes encoding GlpR (suppressors 1–6) and PstS (suppressors 7–9; Fig. 2A; Data Set S1). Importantly, both GlpR and PstS impact regulatory metabolic pathways of the same GPL precursor, G3P. GlpR is a repressor of the *glp* regulon, composed of nine genes that help balance G3P levels (Fig. 2B) (15). Suppressor mutations in GlpR ranged from single nucleotide mutations, deletion of base pairs, and insertion of mobile elements. These substantial genetic changes suggested the mutations resulted in loss of GlpR function. The second major suppressor, disruptions of the gene encoding PstS, impacted the PstSABC complex that activates the DNA-binding regulator PhoB in response to the level of environmental inorganic phosphate (Fig. 2C). Inactivation of any protein in the PstSABC complex results in constitutive activation of PhoB-regulated genes (16). PhoB regulates the expression of *ugpBAECQ* which encodes an ABC transporter system for uptake of G3P, UgpAEC, and the G3P periplasmic binding protein UgpB (Fig. 2C). Disruptive mutations in *pstS* (insertion of mobile elements and large deletions) suggested loss of the encoding protein's function, resulting in constitutive activation of PhoB.


To test if the suppressor mutations were loss-of-function alleles, we generated the double mutants, Δ *plsX* Δ *glpR* and Δ *plsX* Δ *pstS*. We then sought to introduce the *plsY::kan* allele using P1 transduction. The triple mutants were viable, indicating the loss of GlpR or PstS suppressed synthetic lethality. These suppressors suggested that G3P levels must be altered in the *plsXY* double mutant by either removing repression of the *glp* regulon by GlpR or through constitutive activation of PhoB. Notably, initial suppressor mutations that disrupted *glpR* and *pstS* did not result in stably growing strains. Additional colony morphologies appeared upon reviving the bacteria from glycerol stocks. Colonies were re-isolated, re-sequenced, and found to contain secondary suppressors in genes associated with G3P synthesis, including TpiA (suppressors 10–12) and GpsA (suppressor 13; Fig. 2A; Data Set S1). GpsA, a G3P dehydrogenase, directly converts the glycolytic intermediate dihydroxyacetone-phosphate (DHAP) to G3P (7), whereas TpiA acts as an isomerase and balances the cellular levels of glyceraldehyde 3-phosphate (GAP) and DHAP (Fig. 1A inset). These results suggested that loss of *plsXY* required increased levels of G3P, either by pushing synthetic pathways to produce more G3P or to increase its transport. It is likely that the initial *glpR* and *pstS* suppressor mutations were not sufficient to stably increase cytoplasmic G3P levels. Metabolism of G3P is highly tunable through (i) TpiA reversibility and (ii) balance of G3P biosynthesis through GpsA and G3P degradation through GlpD (aerobic) or GlpABC (anaerobic; Fig. 2B) (7, 17). In addition, G3P generation via GlpK (glycerol kinase; Fig. 1A inset) is regulated by a glycolysis intermediate, fructose 1,6-bisphosphate, which is degraded by GlpX (18). It is likely that the secondary mutations were needed to favor one direction in G3P metabolism.

However, GpsA and TpiA both contribute to overall flux of DHAP which can be shunted to a toxic byproduct, methylglyoxal, via MgsA (methylglyoxal synthase; Fig. 1A inset). Toxicity can be overcome in the presence of glutathione, which spontaneously reacts with methylglyoxal (19). To confirm that synthetic lethality of Δ *plsXY* was not due to build-up of methylglyoxal, we aimed to build a Δ *plsX* Δ *mgsA* Δ *plsY::kan* mutant via P1

A

| Attempted Strain | Primary Suppressor | Secondary Suppressor | Predicted G3P Synthesis (WT = +) | Predicted G3P Degradation (WT = +) |
|--|----------------------------|-------------------------|----------------------------------|------------------------------------|
| $\Delta plsX \Delta plsY$ | <i>glpR</i> (regulation) | – | ++ | ++ |
| | <i>glpR</i> (regulation) | <i>gpsA</i> (synthesis) | ++++ | ++ |
| | <i>pstS</i> (regulation) | – | ++ | + |
| | <i>pstS</i> (regulation) | <i>gpsA</i> (synthesis) | ++++ | + |
| $\Delta plsX \Delta glpR \Delta plsY$ | $\Delta glpR$ (regulation) | – | ++ | ++ |
| | $\Delta glpR$ (regulation) | <i>tpiA</i> (balance) | ++++ | ++ |
| $\Delta plsX \Delta pstS \Delta plsY$ | $\Delta pstS$ (balance) | – | ++ | + |
| | $\Delta pstS$ (balance) | <i>gpsA</i> (synthesis) | ++++ | + |
| | | <i>tpiA</i> (balance) | ++++ | + |
| $\Delta plsX \Delta plsY$ short-term evolution | <i>glpR</i> (regulation) | <i>gpsA</i> (synthesis) | ++++ | ++ |

B



C




FIG 2 Isolation of suppressor mutations that rescue $\Delta plsX \Delta plsY$ synthetic lethality. (A) Summary of primary suppressors allowing for the generation of *plsX plsY* double mutants via phage transduction, followed by secondary suppressors that arose after revival from frozen stocks. Outcomes of each suppressor strain are summarized in the rightmost columns regarding predicted changes in G3P concentration. Levels of G3P in WT are shown as “+” to indicate a balance between synthesis and degradation. “Regulation” refers to biological processes that would impact the expression of genes that increase or decrease levels of G3P and substrates for synthesis, while “balance” refers to processes directly involved in synthesis/degradation of G3P. (B) Overview of the *glp* regulon—consisting of nine *glp* genes involved in the regulation of G3P—with orange indicating degradation of G3P and green indicating import or synthesis of G3P. GlpR acts as a repressor for all genes, repressing in the presence of glucose and unbound to DNA in the presence of glycerol or G3P. Suppressors resulting in dysregulation in GlpR could result in constitutive activation of the *glp* regulon. * Indicates anaerobic complex. (C) Inactivation of the PstSABC complex (represented by dashed lines) results in constitutive activation of the Pho regulon, which includes the *ugpBAECQ* operon. UgpBAECQ is involved in breakdown of glycerophosphodiester and import of G3P from the periplasmic space.

phage transduction, but we were unable to obtain colonies despite repeated attempts. Additionally, no suppressors arose in genes related to glutathione synthesis. Therefore, synthetic lethality of $\Delta plsXY$ is not due to growth stasis via methylglyoxal accumulation.

Before investigating how G3P levels were altered, we needed to know how many mutations were necessary to get stable suppression of the synthetic lethality. We turned to a short-term evolution approach to determine what mutations were required to

stabilize growth. Every 24 hours, a culture of $\Delta plsXY$ was back-diluted 1:10 into fresh lysogeny broth (LB) media and incubated at 37°C until the mutant reached an equivalent overnight density compared to wild-type W3110. In a pilot experiment, an evolved strain only obtained single nucleotide mutations in two genes even after 26 days of passaging—*glpR* and *gpsA* (suppressor 14; Fig. 2A; Data Set S1). These results indicated that the secondary mutations likely resulted in stable strains. Altogether, our suppressor analysis suggested that cytoplasmic G3P levels must be increased to support the viability of $\Delta plsXY$.

Increasing G3P concentration rescues $\Delta plsXY$ synthetic lethality

To test if increasing G3P levels suppressed $\Delta plsXY$, we overexpressed WT alleles of GlpK or GpsA (Fig. 1A inset) to artificially increase G3P pools. Overexpression of GlpK or GpsA rescued growth of $\Delta plsXY$ by efficiency of plating assays (Fig. 3A). Noga et al. showed that G3P concentration correlated with increased GPL flux in *E. coli*, but supplementing glycerol to media did not correlate with GPL flux, even though total G3P concentration increased (20). We hypothesized that suppressor mutations worked to increase GPL flux, and therefore, supplementation of glycerol would not rescue $\Delta plsXY$. Supporting this conclusion, exogenous supplementation with 0.2% G3P suppressed synthetic lethality (Fig. 3B), while supplementation with 0.2% glycerol did not (Fig. S2A). Together, these data indicated that $\Delta plsXY$ requires supplementation of G3P to survive. We hypothesized that either $\Delta plsX$ or $\Delta plsY$ may have reduced levels of G3P, contributing to the synthetic lethal phenotype. Thus, we analyzed total G3P pools via liquid chromatography-mass spectroscopy (LC-MS). To our surprise, single mutants, as well as overexpression of PlsX or PlsY, did not have significant changes in the internal G3P pools (Fig. 3C). As a positive control for the dynamic range of our G3P quantification, a *glpD::kan* mutant, previously shown to increase cellular concentrations of G3P (17), was also assessed and showed an increased concentration of G3P (Fig. 3C).

In *Bacillus subtilis*, a Gram-positive bacterium with only PlsX/Y (YneS/YgiH), it was shown that supplementation with either glycerol or G3P could rescue a temperature-sensitive allele of *plsX* (*yneS-ts*) (12). In this organism, deletion of *plsX* (*yneS*) or *plsY* (*ygiH*) is lethal, as there is no PlsB to recover LPA synthesis. However, it is worth noting that *B. subtilis* can also generate acyl-PO₄ from exogenous fatty acids via the FakAB system, providing additional substrate for PlsY. Rescue of the *plsX-ts* mutant with exogenous glycerol or G3P suggests that an increase in PlsY activity was necessary, likely because acyl-PO₄ concentration was low. It is not surprising that *B. subtilis* and *E. coli* $\Delta plsXY$ mutants would vary in the ability of glycerol to rescue lethality. We speculate that as a Gram negative, *E. coli* may require tighter control of the conversion of glycerol to G3P to balance the synthesis of OM lipids. Previously, it was shown that a *plsXY* double mutant was viable when PlsB was expressed *in trans* (12). We sought to validate this rescue of $\Delta plsXY$ synthetic lethality via overexpression of PlsB as it would support that pushing GPL synthesis is essential in this genetic background. A $\Delta plsY::kan$ allele was introduced via P1 phage transduction into $\Delta plsX$ while overexpressing PlsB *in trans* and vice versa ($\Delta plsX::kan$ into a $\Delta plsY$ recipient while overexpressing PlsB *in trans*). Cells were grown under inducing conditions (arabinose) overnight, washed, and switched to repressing (glucose) conditions. PlsB overexpression suppressed the synthetic lethality of the *plsXY* double mutant by efficiency of plating assay (Fig. S2B). Together, rescue by PlsB overexpression and heightened G3P suggested that LPA synthesis needed to be pushed to suppress the lethal phenotype of $\Delta plsXY$. These results indicate that PlsXY likely contributes to LPA synthesis, albeit a minor contribution compared to PlsB because individually PlsX and PlsY are not essential. Individual loss of PlsX or PlsY would have the same impact to LPA synthesis as loss of both; therefore, reduced LPA synthesis would have to be only one facet of why *plsX* and *plsY* were synthetically lethal.




FIG 3 Increasing the level of G3P rescues $\Delta plsX \Delta plsY$ synthetic lethality. (A) Overexpression of GpsA or GlpK from a plasmid with an arabinose-inducible promoter rescues synthetic lethality of $\Delta plsX \Delta plsY$. Serial dilutions of indicated strains were spotted on LB amp in repressing (0.02% fucose) or inducing (0.02% arabinose) conditions and incubated at 37°C. (B) Supplementation of G3P rescues synthetic lethality of $\Delta plsX \Delta plsY$. Serial dilutions of indicated strains were spotted on LB or LB supplemented with 0.2% G3P and incubated at 37°C. Data in panels A and B are representative of three biological replicates. (C) G3P concentration in $\Delta plsX$ (p-PlsX) and $\Delta plsY$ (p-PlsY) does not significantly change. As expected, G3P concentration increases in a $glpD::kan$ mutant. Error bars in panel C represent SD from six technical replicates, and data are representative of two biological replicates. **, $P \leq 0.01$

Loss of PlsX results in dysregulation of FASII

Next, we tried to further distinguish what additional phenotypes contributed to the $\Delta plsXY$ synthetic lethality. We hypothesized that $\Delta plsXY$ may have an imbalance in other GPL precursors, namely acyl-ACPs. Alterations to the quantity and composition of acyl-ACP pools are a known regulatory mechanism for both the total amount of fatty acid synthesis in the cell and for the balance between GPL and LPS synthesis (21). Fatty acid precursors are finely tuned during elongation via FASII as enough shorter chain acyl-ACPs (C12 and C14) are needed to support LPS synthesis, while sufficient fatty acids

must continue through elongation to produce longer acyl-ACPs (C16 and C18) required for GPL synthesis. Proper LPS/GPL synthesis is maintained by the balanced activities of LpxC (deacetylase) that commits C14-ACPs to LPS synthesis (22) and FabZ (dehydratase) that continues the elongation of acyl-ACPs for GPL synthesis (23). Additional balance is maintained through competition for fatty acids between GPL synthesis and FASII. If acyl-ACPs are not utilized for GPL synthesis, they can continue to be elongated. Accumulation of long-chain acyl-ACPs (e.g., C20-ACP) indicates that the incorporation of fatty acids into GPLs has slowed, providing a cellular signal that FASII flux is too high or indicating a decreased cellular demand for GPL synthesis. Such long-chain acyl-ACPs participate in feedback inhibition by binding to the FASII initiation complex, AccABCD (ACC), reducing FASII flux (Fig. 4A) (13). ACC generates malonyl-CoA, a metabolite that is solely consumed by FASII, which is converted to malonyl-ACP by FabD to prime for elongation.

To test if $\Delta plsX$ or $\Delta plsY$ impacted FASII, we quantified the pool of acyl-ACPs. While malonyl-ACP concentrations are highly sensitive to FASII flux (20), there are three possible alterations to the elongated acyl-ACP pools that would support distinct hypotheses for the role of one of our proteins. The first possible result was that total acyl-ACPs could be decreased, suggesting that either PlsX or PlsY may help to stimulate a step of FASII initiation. A second possibility was that there could be an accumulation of medium-chain (C12 and C14) acyl-ACPs, which may increase LPS flux and reduce the quantity of acyl-ACPs being elongated for GPL flux. This result would suggest that PlsX or PlsY was critical for regulating the balance between LPS and GPLs, possibly through impacting LpxC or FabZ activity. The third possibility was that longer chain (C18 and C20) acyl-ACPs could accumulate, which would concomitantly result in feedback inhibition of FASII initiation. This result would suggest that PlsX or PlsY had a role in preventing long-chain acyl-ACP accumulation.

Loss of PlsY had no changes to the overall long-chain acyl-ACP pools—in terms of the presence of new acyl-ACP species (Fig. 4B). In contrast, loss of PlsX resulted in a profile consistent with the third hypothesis—increased C18 acyl-ACPs and appearance of C20 long-chain acyl-ACPs (Fig. 4B). Overexpression of PlsX *in trans* in $\Delta plsX$ recovered the accumulation of long-chain acyl-ACPs (Fig. S3). This complementation in $\Delta plsX$ also supports the lack of polar effects on FASII genes downstream of *plsX*. Overexpression of PlsY in $\Delta plsY$ did not have any impact on the quantity of long-chain acyl-ACPs in the cell (Fig. S3). Acyl-ACPs of 16-, 18-, and 20-carbon length have been shown to inhibit ACC (13). This result suggested that PlsX has a regulatory role in preventing the accumulation of long-chain acyl-ACPs in a manner that is independent of the production of LPA because this impact is not seen in $\Delta plsY$ which would have the same, albeit minor, reduction of LPA production as $\Delta plsX$. These results are consistent with PlsX and PlsY each having independent cellular roles in addition to their combined role in LPA synthesis.

We sought to determine if the accumulation of long-chain fatty acids in $\Delta plsX$ was enough to substantially repress FASII initiation and therefore cause synthetic lethality of a $\Delta plsXY$ double mutant. To test this, we utilized the antibiotic cerulenin which slows FASII by irreversibly inhibiting FabB/F/H, three FASII enzymes crucial for elongation of fatty acids (Fig. 4A) (24, 25). This inhibition of FASII would mimic the possible ACC inhibition from long-chain acyl-ACP accumulation in *plsX* mutants. The *plsY* mutant was hypersensitive to inhibition by cerulenin, indicating that other mechanisms of slowing FASII, like accumulation of long-chain fatty acids in $\Delta plsX$, are toxic when combined with *plsY* deletion (Fig. 4C). Cerulenin hypersensitivity of $\Delta plsY$ was also complemented by expressing PlsY *in trans* (Fig. 4C). Together, these results suggested that PlsX has an unprecedented role in fine-tuning FASII to prevent the accumulation of long-chain acyl-ACPs.




FIG 4 Loss of PlsX causes dysregulation of FASII. (A) Build-up of long-chain acyl-ACPs feedback inhibit the AccABCD complex which initiates FASII, ultimately slowing elongation by reducing the level of malonyl-CoA. Cerulenin, an irreversible inhibitor of FabB and FabF, slows FASII. (B) Quantification of total long-chain acyl-ACPs in $\Delta plsX$ shows increased C18:0/1-ACP, as well as the presence of C20:0/1-ACP. The latter is barely detected in both WT and $\Delta plsY$. Technical triplicates are shown and are representative of three biological sets. (C) Growth curve showing the sensitivity of $\Delta plsY$ to the presence of 45 $\mu\text{g}/\text{mL}$ cerulenin. Overexpression of PlsY *in trans* rescues sensitivity. Strains were grown in LB amp under inducing (100 μM IPTG) conditions. Error bars represent SD from three biological replicates and are not shown when smaller than the symbol.

PlsX actively impacts FASII via FadD

How might PlsX mediate alterations in the fatty acid pool? If PlsX is consuming long-chain acyl-ACPs (16C and 18C) in parallel with PlsB, then it acts to effectively decrease the average chain length of acyl-ACPs undergoing elongation due to a shifting in the balance between long-chain acyl-ACP elongation (FASII) and incorporation into GPLs (via PlsY). This modulation would occur as FASII acts to balance the appropriate length of acyl-ACP with cellular demand—C12/14 for LPS synthesis and C16/18 for GPL synthesis—while also working to prevent elongation to C20. PlsX might also influence the fatty acid pool by the production of free fatty acids (via hydrolysis). Typically, PlsX converts an acyl-ACP into an acyl-PO₄, a substrate used solely by PlsY. However, these acyl-PO₄(s) are highly labile and can hydrolyze to a free fatty acid if not used quickly (26). The free fatty acid can then be converted into an acyl-CoA by FadD, a fatty acid-CoA ligase, and be degraded through β -oxidation (Fig. 5A) (27). In this way, PlsX activity may help to control the level of acyl-ACPs within the cell.

To test if PlsX was capable of redirecting excess acyl-ACPs into β -oxidation, we sought a genetic background with excessive production of acyl-ACPs. When FadR (DNA-binding dual regulator) is present and in an active conformation, FASII genes are activated and β -oxidation genes are downregulated to balance the synthesis and degradation of acyl-chains. However, upon binding an acyl-CoA, FadR-DNA interactions are disrupted, resulting in decreased expression of FASII genes, a reduction in acyl-ACP pools, and derepression of β -oxidation genes (28). Overexpression of FadR increases fatty acids that are of appropriate length for GPL synthesis, leading to increased lipid membrane content that correlated with increased cellular area (29). We hypothesized that overexpression of PlsX would rescue this phenotype by pulling excess acyl-ACPs from FASII and pushing




FIG 5 Overexpression of PlsX reduces increased cell size when FASII flux is upregulated. (A) In *E. coli*, FASII and β -oxidation (β -ox) are highly regulated pathways for synthesis and degradation of acyl-ACPs or acyl-CoAs, respectively. One such enzyme for regulation is FadR, which activates transcription of FASII enzymes while repressing transcription of β -ox enzymes. PlsX pulls acyl-ACP from FASII, generating an acyl-PO₄ which can be used by PlsY for GPL synthesis or spontaneously degraded to a free fatty acid. FadD converts free fatty acids to acyl-CoAs for degradation through β -ox. If the acyl-CoAs are of appropriate length for GPL synthesis, PlsB/C can utilize them. (B) Phase contrast microscopy of $\Delta plsY$ and $\Delta plsY \Delta fadD$ with overexpression of FadR and PlsX at 1,000 \times magnification. Scale bar is 5 μ m. A single cell from the field of view is highlighted with a $\times 2$ magnified inset. (C) Morphological changes associated with overexpression of FadR in $\Delta plsY$ are partially rescued by simultaneous overexpression of PlsX as shown via a decrease in overall cell area. (D) Decrease in area by PlsX when FadR is overexpressed is abolished when FadD is deleted, suggesting this response is FadD-mediated. Data in panels C and D represent mean values with the SD from >5 fields of view and >100 cells per strain. Data are representative of biological triplicates. For panels B–D, OD₆₀₀ for cultures was within 10% variance. Significance was calculated using Brown-Forsythe and Welch ANOVA tests. **, $P \leq 0.01$; ns, not significant.

flux toward FadD, generating acyl-CoAs (Fig. 5A). While FadR would act to repress *fad*, there are still basal levels of *fad* transcripts due to product feedback inhibition on FadR. To ensure overexpression of PlsX does not push acyl-PO₄ toward GPL synthesis, we performed these experiments in a *plsY* mutant.

Overexpression of PlsX alone in $\Delta plsY$ did not alter cell size, suggesting that acyl-CoAs generated through FadD are either not being utilized by PlsB/C for GPL synthesis or are produced in too little quantity to detect global changes (Fig. 5B). With FadR overexpression, cells behave as expected, showing an overall increase in cell area and length. In $\Delta plsY$ overexpressing both FadR and PlsX, there is visible partial rescue in cell size confirmed by cell measurements (Fig. 5B and C; Fig. S4A through C). We contribute incomplete rescue to the complex regulation occurring within the cell regarding FadR. Due to feedback inhibition of acyl-CoAs on FadR, β -oxidation proteins would rise and decrease acyl-CoA pools, thereby relieving FadR inhibition—forming a bottleneck at FadD for acyl-CoA degradation.

To test if rescue of $\Delta plsY$ overexpressing both FadR and PlsX was FadD mediated, we repeated microscopy in $\Delta plsY \Delta fadD$ and saw that PlsX overexpression failed to rescue FadR overexpression defects (Fig. 5B and D). These findings were confirmed by measuring changes in cell morphology (Fig. 5C and D; Fig. S4A through C) and suggest that PlsX may work to fine-tune FASII in a FadD-dependent manner—whether that be

by increasing β -oxidation or through feedback regulation of FadR. Altogether, these data suggested that PlsX helps to prevent the accumulation of fatty acids.

Suppressors that rescue growth of $\Delta plsXY$ do not rescue phenotypes associated with single $plsX$ and $plsY$ mutants

With a possible secondary role for PlsX identified, we were curious if suppressor mutations that restore growth to $\Delta plsXY$ would rescue phenotypes observed when only $plsX$ or $plsY$ was absent. Deletion of $glpD$ increased G3P levels (Fig. 3D), and given that increased G3P correlates with increased GPL flux (20), we suspected that loss of $glpD$ would rescue $\Delta plsXY$. We first aimed to confirm that $\Delta glpD$ rescues synthetic lethality of $\Delta plsXY$ through co-transduction linkage ($\Delta plsY \Delta yjH::kan$). We found that co-transduction of the $\Delta plsY$ allele linked to $\Delta yjH::kan$ was possible into a $\Delta plsX \Delta glpD$ strain, showing that $\Delta glpD$ does rescue lethality (Table S1). Next, we questioned if $glpD$ deletion would rescue the secondary impacts of losing PlsX and PlsY individually and introduced a $glpD$ deletion into both $\Delta plsX$ and $\Delta plsY$.

Total acyl-ACPs levels were quantified in $\Delta glpD::kan$ and $\Delta plsX \Delta glpD::kan$ to determine if increasing G3P levels would reduce long-chain acyl-ACP build-up when PlsX was absent. As shown earlier in Fig. 4B, $\Delta plsX$ has an increase in C18:0/1-ACPs, as well as the appearance of C20:0/1-ACPs, whereas the deletion of $glpD$ alone had no effect (Fig. 6A). Deletion of $glpD$ in $\Delta plsX$ did not restore WT levels of long-chain acyl-ACPs (Fig. 6A). To test whether deletion of $glpD$ could impact a $plsY$ -specific phenotype, we evaluated the $plsY$ mutant's sensitivity to cerulenin. Cerulenin slightly decreased the growth of $\Delta glpD$; however, deletion of $glpD$ did not rescue sensitivity of $\Delta plsY$ (Fig. 6B). Together, these data supported that $\Delta plsXY$ suppressors do not restore the additional roles of PlsX and PlsY outside of the canonical pathway for LPA synthesis.

DISCUSSION

By the mid-90s, the majority of the enzymatic machinery required for FASII and PA synthesis in Gram-negative bacteria had been identified, including PlsB and PlsC. However, the complex mechanisms governing these processes, as well as some of the key enzymatic players, remained unknown. Specifically, PlsX was a known acyltransferase, though not well-studied (30), and PlsY remained undiscovered. Consequently, dogma of that time centered PlsB/C as the traditional pathway for PA synthesis. It was not until 10 years later that Lu et al. (5) discovered the novel acyltransferase PlsY in Gram-positive bacteria. This discovery "Rock"-ed the field by demonstrating that the PlsX/Y pathway was the most wide-spread system for initiation of PA synthesis in bacteria, not PlsB. Interestingly, it became clear that various species of proteobacteria evolved to maintain both PlsB and PlsX/Y (8). This conservation piqued the question of why some Gram-negative species require a seemingly redundant system?

In Gram-negative bacteria, PlsB is more deeply studied than PlsX and PlsY (31) since single $plsX$ and $plsY$ deletions are viable and $plsB$ is essential. The synthetic lethality of the $plsXY$ mutant has remained understudied. Because disabling either enzyme eliminates the PlsX/Y route to PA synthesis, synthetic lethality suggests that PlsX and PlsY have multiple roles in the Gram-negative cell outside of the canonical PA synthesis pathway (Fig. 6C). Based on our data, we propose three roles of PlsX/Y that together contribute to the synthetic lethality. Gram-positive and Gram-negative PlsX/Y contain high conservation and homology, suggesting maintenance of the enzymatically proven activity (5, 32). Furthermore, our suppressors (discussed below) of $plsXY$ synthetic lethality would all push PlsB activity, suggesting that a contribution to LPA synthesis is one facet of the synthetic effect. Thus, for role (i), we agree with existing literature that PlsX and PlsY together participate in PA production, although in minor quantities (Fig. 6C). For role (ii), our data suggest that PlsX in Gram-negative bacteria prevents accumulation of long-chain acyl-ACPs and actively connects FASII and β -oxidation in a FadD-dependent manner (Fig. 6C, discussed further below). Finally, because single $\Delta plsX$ mutants are viable and would be missing role (i and ii), we conclude that PlsY must have a third role




FIG 6 Three biological roles contribute to synthetic lethality of $\Delta plsXY$. (A) Quantification of total long-chain acyl-ACPs in $\Delta plsX$ and $\Delta plsX \Delta glpD::kan$ shows increased C18:0/1-ACP, as well as the presence of C20:0/1-ACP. The latter is barely detected in both WT and $\Delta glpD::kan$. Error bars represent SD from three technical replicates. (B) Growth curve showing the sensitivity of $\Delta plsY$ to the presence of 45 $\mu\text{g}/\text{mL}$ cerulenin. Deletion of $\Delta glpD::kan$ grows similarly to WT, while $\Delta plsY \Delta glpD$ does not rescue growth in the presence of cerulenin. Error bars represent SD from three biological replicates and are not shown when smaller than the symbol. (C) PlsXY has redundant roles with PlsB for synthesis of PA (i). Data presented here suggests that PlsX prevents accumulation of long-chain acyl-ACPs in a FadD-dependent manner (ii), while PlsY must play an additional, but unknown tertiary role (iii).

in the cell that has yet to be discovered and contributes to the synthetic lethality of $plsXY$ double mutants [Fig. 6C, role (iii)]. This potential additional role of PlsY is actively under investigation in our laboratory. Since $\Delta plsY$ would have partial disruption of PA synthesis [role (i)] along with loss of role (iii), we conclude that the loss of all three roles has to contribute to synthetic lethality (Fig. 6C). Altogether, our findings support that PlsX and PlsY contribute to three roles in the cell, and it is the loss of all three roles that is synthetically lethal.

We validated that overexpression of PlsB (Fig. S2B) rescued synthetic lethality of $\Delta plsXY$, suggesting that a reduction of PA synthesis [role (i)] contributed to lethality. This conclusion was also supported by rescue with GlpK or GpsA overexpression (artificially increasing G3P concentration; Fig. 3A) and exogenous supplementation of G3P (Fig. 3B). Heath and Rock (33) worked with isolated mutants that depend on G3P for growth (34) and characterized the $plsB26$ allele which resulted in a variant with elevated K_m for G3P. However, this allele alone did not cause cells to become dependent on G3P. A second frameshift mutation in $plsX$ ($plsX50$) (35) combined with $plsB26$ resulted in a G3P-dependent strain (36). These findings suggested that if PlsB activity is compromised, PlsX activity is able to contribute to PA synthesis [role (i)]. Our work similarly found that increasing G3P and altering flux toward PA synthesis rescued the growth of the $plsXY$ double mutant.

Outside of role (i), we propose that PlsX functions to connect FASII and β -oxidation [role (ii)]. This role would be specific to Gram-negatives as many Gram-positive bacteria do not contain homologous genes for β -oxidation (37) and others have incomplete or undiscovered pathways (8). While previous work suggested a role for PlsX in acyl-ACP regulation (12), we further propose that PlsX works in a FadD-dependent manner to prevent the accumulation of longer chain acyl-ACPs (e.g., C20:0-ACP). PlsX pulls acyl-ACP from FASII. If the cell needs production of GPLs, then these intermediates would be quickly consumed by PlsY. However, if PlsY activity is low or inhibited then the acyl-PO₄ would spontaneously dephosphorylate into a free fatty acid. Free fatty acids can then be

converted to acyl-CoA's by FadD for reutilization or degradation. Supporting this theory, overexpression of the thioesterase TesA has been reported to rescue a $\Delta plsXY$ mutant (12). TesA is normally a periplasmic thioesterase, but overexpression was found to result in trapping of the enzyme in the cytoplasm, allowing for cleavage of acyl-thiols. In this way, cytoplasmic TesA cleaves acyl-ACPs similar to the hypothesized turnover of acyl-PO₄ via PlsX. TesA overexpression would therefore rescue a $\Delta plsX \Delta plsY$ mutant as it would restore loss of role (ii).

FadD-generated acyl-CoA molecules have three possible directions in Gram-negative cells. (i) PlsB and PlsC may utilize an acyl-CoA of appropriate lengths for PA synthesis. (ii) The acyl-CoA may be degraded through β -oxidation. (iii) FadR may bind to the longer chain acyl-CoA, causing changes to regulation of both FASII (de-activation) and β -oxidation (de-repression). Overall, these data suggest that *E. coli* produces more acyl-ACPs than are required and that PlsX is needed to prevent the accumulation of long-chain acyl-ACP by maintaining a proper balance between fatty acid elongation and incorporation into GPLs.

Role (iii) of PlsY has yet to be elucidated. Recently, PlsY was demonstrated to interact with YejM (38), a regulator of LPS synthesis. This is a new and rapidly expanding field of research. LpxC is proteolytically regulated by the adapter protein LapB and the protease FtsH (21). LapB is occluded through interaction with an IM sensor, YejM, and released when LPS accumulates in the outer leaflet of the IM, allowing for degradation of LpxC (21). In addition to serving as an adaptor for FtsH cleavage, LapB was also recently shown to bind and inhibit LpxC activity (39), indicating the many nuances to this tight regulation. We are actively working to elucidate the role that PlsY may play in modulating the activity of YejM, or vice versa. Altogether, our findings suggest that maintenance of the PlsX/Y pathway in Gram-negative organisms provides a fitness advantage by allowing the cell to fine-tune the level of major lipids. This control is critical for overall cell envelope homeostasis and for maintaining OM asymmetry.

The choice to exploit PlsB or PlsX/Y as the major LPA synthesis pathway also conveniently correlates with differences in how Gram-negatives and Gram-positives utilize exogenous fatty acids from the environment. In Gram-positives, which possess only PlsX/Y, exogenous fatty acids are converted to acyl-PO₄ by the FakA/B system (27), which can be used by PlsY. Thus, the combination of PlsY and FakA/B allows Gram positives to grow on exogenous fatty acids. The robust outer membrane of Gram-negative species requires the import of exogenous fatty acids through FadL/D, which instead converts fatty acids into acyl-CoAs. PlsB can utilize acyl-CoAs, whereas PlsX/Y cannot. Therefore, the combination of PlsB and FadL/D achieve the same goal of utilization of exogenous fatty acids for Gram-negatives. By utilizing PlsB to drive the majority of LPA synthesis from both *de novo* synthesized (acyl-ACPs) and exogenous (acyl-CoA) fatty acids, perhaps Gram-negative organisms like *E. coli* were then free to repurpose PlsX/Y in ways to balance lipid synthesis and promote outer membrane stability.

MATERIALS AND METHODS

Bacterial growth conditions

Bacteria were grown in LB or on LB agar at 37°C with appropriate supplementation—ampicillin (amp; 100 μ g/mL), kanamycin (kan; 30 μ g/mL), chloramphenicol (cam; 30 μ g/mL), cerulenin (45 μ g/mL), L-arabinose (wt/vol), D-glucose (wt/vol), D-fucose (wt/vol), glycerol (vol/vol), or G3P (wt/vol) as indicated in figure legends. For growth curves, bacteria were grown in 20 mm test tubes with 5 mL of media, unless otherwise stated, and OD₆₀₀ was measured with 150 μ L of culture in a 96-well plate on the BioTek Epoch 2 plate reader.

Strain and plasmid construction in *E. coli*

All strains, plasmids, and oligonucleotides used in this study are listed in the Data Set S1. Strains were generated using P1 phage transduction from Keio collection strains

as previously described (40). Kanamycin cassettes were removed using flippase/flipase recognition target site-specific recombination activity from the pCP20 plasmid as previously described (41). *plsX*, *glpK*, *gpsA*, and *plsB* were cloned into pCV1 or pCV3 plasmids utilizing BspQI cloning as previously described (42). Briefly, W3110 genomic DNA was isolated with the Easy-DNA (Invitrogen) kit and the genes of interest amplified by PCR using their respective primers. PCR products were digested and ligated with plasmid using the Fast-Link DNA Ligation Kit (Avantor) and transformed into DH5 α . Construction of pWSKI was previously reported (43). Briefly, pBAD18::*fadR* (EcoRI and KpnI) was generated via restriction enzyme cloning by digestion, ligation, and transformation into DH5 α . Genscript services were used for subcloning of *PlsX* (NotI and BamHI) and *PlsY* (NotI and EcoRI) into pWSKI. Plasmids were verified using whole-plasmid sequencing (Plasmidsaurus).

Depletion growth curve for demonstrating $\Delta plsX \Delta plsY$ synthetic lethality

One mL of overnight bacterial cultures in LB amp 0.02% glucose was washed twice and resuspended in 1 mL of fresh LB. Bacteria were inoculated to an OD₆₀₀ 0.001 in 200 μ L of appropriate media in a 96-well plate and incubated for 3 hours at 37°C with shaking. Cultures were back-diluted again to an OD₆₀₀ 0.001 in fresh media and incubated for an additional 2 hours. Cultures were back-diluted once more to OD₆₀₀ 0.01 and incubated at 37°C.

Efficiency of plating assays

Overnight bacterial cultures were standardized by OD₆₀₀ and serially diluted 1:10 in LB media in a 96-well plate. Dilutions were spotted onto the indicated LB antibiotic plates with a Replica Plater for 96 well plate (Sigma-Aldrich) and incubated for 16 hours at 37°C.

RNA-seq analysis

Overnight bacterial cultures were back-diluted in 5 mL of LB to an OD₆₀₀ 0.05 and incubated to an OD₆₀₀ ~0.8. One mL of culture was combined with 2 mL of RNAprotect (QIAGEN), vortexed for 15 seconds, and incubated at room temperature for 5 minutes. The mixture was centrifuged at 5,000 $\times g$ for 10 minutes and the supernatant discarded. Samples were prepped in biological triplicates. Library preparation, rRNA depletion, and RNA sequencing were carried out by SeqCenter, LLC using Illumina RNA Sequencing with ~12 M RNA reads/sample. RNA-seq analysis was performed using QIAGEN CLC Genomics Workbench.

Selection of suppressors that restore growth to *plsXY* double mutants

Overnight cultures of either $\Delta plsX$ or $\Delta plsY$ were used as the recipient strain for generalized P1 phage transduction with $\Delta plsX::kan$ or $\Delta plsY::kan$ generated from the Keio collection. Strains were plated on LB kan supplemented with 5 mM NaCitrate and incubated until colonies formed at 37°C. After isolation, suppressors were cultured in 5 mL of LB, and 1 mL of pelleted overnight culture was sent to SeqCenter, LLC for DNA extraction and sequencing using Illumina Whole-Genome Sequencing with 200 Mbp/sample of data resulting in ~1.5 M reads. Sequencing analysis was performed using QIAGEN CLC Genomics Workbench and *E. coli* W3110 DNA sequence.

Selection of *plsXY* double mutants in the presence of G3P

Overnight cultures of either $\Delta plsX$ or $\Delta plsY$ were used as the recipient strain for generalized P1 phage transduction with $\Delta plsX::kan$ or $\Delta plsY::kan$ generated from the Keio collection. Strains were plated on LB kan supplemented with 5 mM NaCitrate and 0.2% G3P and incubated until colonies formed at 37°C. After isolation, suppressors were cultured for 6 hours in 5 mL of LB supplemented with 0.2% G3P, and 1 mL of culture

was sent for WGS as described above. For efficiency of plating assays, 0.2% G3P was supplemented in the overnight cultures, and cells were washed twice before plating.

Co-transduction for synthetic lethality and rescue of a *plsXY* double mutant

Overnight cultures of either W3110, $\Delta plsX$, $\Delta plsY$, or $\Delta plsX \Delta glpD$ were used as the recipient strain for generalized P1 phage transduction with $\Delta plsX \Delta thrO::kan$ or $\Delta plsY \Delta yjH::kan$ generated using the Keio collection. Strains were plated on LB kan supplemented with 5 mM NaCitrate and incubated until colonies formed at 37°C. Approximately 30 colonies were patched to LB kan and incubated overnight at 37°C. Patches were PCR screened for gene deletion and gene duplication.

LC/MS quantification of ACP intermediates and analysis of G3P

Samples were collected and analyzed using a previously reported method (20).

Phase-contrast microscopy

Overnight cultures were back-diluted to an $OD_{600} \sim 0.05$. Strains were incubated for 5 hours (OD_{600} was within 10% variance) in the presence of amp cam and 0.2% arabinose, and 1 μ L was spotted onto a coverslip and an LB agar pad placed on top. Cells were imaged at 1,000 \times magnification on a Nikon Eclipse T12 equipped with Orca-Fusion Digital Camera C14440 in phase-contrast. Calibration was performed with a 1 mm ruler and 0.01 mm divisions of an Azzota Corp. micrometer slide. Measurements were performed on >5 fields of view and >100 cells per strain in biological triplicate as previously described (44).

ACKNOWLEDGMENTS

We thank Dr. Adja Zoumaro-Djajoon for LCMS analysis. We gratefully acknowledge funding from the National Institutes of Health, grants AI176776, AI138576, and AI150098 and funding from the Army Research Office (ARO, <http://www.arl.army.mil/>) grant W911NF2010195 to M.S.T. G.B. was supported by a startup grant from the TU Delft Department of Bionanoscience.

AUTHOR AFFILIATIONS

¹Department of Microbiology, College of Art and Sciences; University of Georgia, Athens, Georgia, USA

²Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA

³Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology, Delft, Netherlands

AUTHOR ORCIDs

Audrey N. Rex  <http://orcid.org/0000-0002-7305-3053>

Gregory Bokinsky  <http://orcid.org/0000-0002-7256-4492>

M. Stephen Trent  <http://orcid.org/0000-0001-6134-1800>

FUNDING

| Funder | Grant(s) | Author(s) |
|---|--|------------------|
| HHS NIH National Institute of Allergy and Infectious Diseases (NIAID) | R01 AI174416, R01 AI176776, R01 AI138576 | M. Stephen Trent |

| Funder | Grant(s) | Author(s) |
|---|------------------|------------------|
| DOD USA AFC CDC ARO Life Sciences Division, Army Research Office (Life Sciences Division ARO) | W911NF-19-S-0008 | M. Stephen Trent |

AUTHOR CONTRIBUTIONS

Audrey N. Rex, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft | Brent W. Simpson, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing | M. Stephen Trent, Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – review and editing.

DIRECT CONTRIBUTION

This article is a direct contribution from M.S.T., a Fellow of the American Academy of Microbiology, who arranged for and secured reviews by Thomas Bernhardt, Harvard Medical School, and Marcin Grabowicz, Emory University School of Medicine.

ADDITIONAL FILES

The following material is available [online](#).

Supplemental Material

Data Set S1 (mBio02969-24-s0001.xlsx). Description of strains, plasmids, and RNA-seq data.

Supplemental Material (mBio02969-24-s0002.pdf). Figures S1 to S4; Table S1.

REFERENCES

- Silhavy TJ, Kahne D, Walker S. 2010. The bacterial cell envelope. *Cold Spring Harb Perspect Biol* 2:a000414. <https://doi.org/10.1101/cshperspect.a000414>
- Emiola A, Andrews SS, Heller C, George J. 2016. Crosstalk between the lipopolysaccharide and phospholipid pathways during outer membrane biogenesis in *Escherichia coli*. *Proc Natl Acad Sci U S A* 113:3108–3113. <https://doi.org/10.1073/pnas.1521168113>
- Henderson JC, Zimmerman SM, Crofts AA, Boll JM, Kuhns LG, Herrera CM, Trent MS. 2016. The power of asymmetry: architecture and assembly of the Gram-negative outer membrane lipid bilayer. *Annu Rev Microbiol* 70:255–278. <https://doi.org/10.1146/annurev-micro-102215-095308>
- Antimicrobial Resistance Collaborators. 2022. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet Lond Engl* 399:629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
- Lu Y-J, Zhang Y-M, Grimes KD, Qi J, Lee RE, Rock CO. 2006. Acyl-phosphates initiate membrane phospholipid synthesis in Gram-positive pathogens. *Mol Cell* 23:765–772. <https://doi.org/10.1016/j.molcel.2006.06.030>
- Cronan JE, Rock CO. 2008. Biosynthesis of membrane lipids. *EcoSal Plus* 3. <https://doi.org/10.1128/ecosalplus.3.6.4>
- Yao J, Rock CO. 2013. Phosphatidic acid synthesis in bacteria. *Biochim Biophys Acta* 1831:495–502. <https://doi.org/10.1016/j.bbali.2012.08.018>
- Zhang Y-M, Rock CO. 2008. Thematic review series: glycerolipids. Acyltransferases in bacterial glycerophospholipid synthesis. *J Lipid Res* 49:1867–1874. <https://doi.org/10.1194/jlr.R800005-JLR200>
- Lu Y-J, Zhang F, Grimes KD, Lee RE, Rock CO. 2007. Topology and active site of PlsY: the bacterial acylphosphate:glycerol-3-phosphate acyltransferase. *J Biol Chem* 282:11339–11346. <https://doi.org/10.1074/jbc.M700374200>
- Saksena S, Forbes K, Rajan N, Giles D. 2023. Phylogenetic investigation of Gammaproteobacteria proteins involved in exogenous long-chain fatty acid acquisition and assimilation. *Biochem Biophys Rep* 35:101504. <https://doi.org/10.1016/j.bbrep.2023.101504>
- Ray TK, Cronan JE. 1987. Acylation of glycerol 3-phosphate is the sole pathway of *de novo* phospholipid synthesis in *Escherichia coli*. *J Bacteriol* 169:2896–2898. <https://doi.org/10.1128/jb.169.6.2896-2898.1987>
- Yoshimura M, Oshima T, Ogasawara N. 2007. Involvement of the YneS/YgiH and PlsX proteins in phospholipid biosynthesis in both *Bacillus subtilis* and *Escherichia coli*. *BMC Microbiol* 7:69. <https://doi.org/10.1186/1471-2180-7-69>
- Davis MS, Cronan JE. 2001. Inhibition of *Escherichia coli* acetyl coenzyme A carboxylase by acyl-acyl carrier protein. *J Bacteriol* 183:1499–1503. <https://doi.org/10.1128/JB.183.4.1499-1503.2001>
- Douglass MV, Cléon F, Trent MS. 2021. Cardiolipin aids in lipopolysaccharide transport to the Gram-negative outer membrane. *Proc Natl Acad Sci U S A* 118:e2018329118. <https://doi.org/10.1073/pnas.2018329118>
- Larson TJ, Ye SZ, Weissenborn DL, Hoffmann HJ, Schweizer H. 1987. Purification and characterization of the repressor for the sn-glycerol 3-phosphate regulon of *Escherichia coli* K12. *J Biol Chem* 262:15869–15874. [https://doi.org/10.1016/S0021-9258\(18\)47669-7](https://doi.org/10.1016/S0021-9258(18)47669-7)
- Hoffer SM, Tommassen J. 2001. The phosphate-binding protein of *Escherichia coli* is not essential for Pi-regulated expression of the pho regulon. *J Bacteriol* 183:5768–5771. <https://doi.org/10.1128/JB.183.19.5768-5771.2001>
- Spoering AL, Vulic M, Lewis K. 2006. GlpD and PlsB participate in persister cell formation in *Escherichia coli*. *J Bacteriol* 188:5136–5144. <https://doi.org/10.1128/JB.00369-06>
- Thorner JW, Paulus H. 1973. Catalytic and allosteric properties of glycerol kinase from *Escherichia coli*. *J Biol Chem* 248:3922–3932. [https://doi.org/10.1016/S0021-9258\(19\)43821-0](https://doi.org/10.1016/S0021-9258(19)43821-0)
- Ferguson GP, Booth IR. 1998. Importance of glutathione for growth and survival of *Escherichia coli* cells: detoxification of methylglyoxal and

- maintenance of intracellular K⁺. *J Bacteriol* 180:4314–4318. <https://doi.org/10.1128/JB.180.16.4314-4318.1998>
20. Noga MJ, Büke F, van den Broek NJF, Imholz NCE, Scherer N, Yang F, Bokinsky G. 2020. Posttranslational control of PlsB is sufficient to coordinate membrane synthesis with growth in *Escherichia coli*. *mBio* 11:e02703-19. <https://doi.org/10.1128/mBio.02703-19>
21. Simpson BW, Douglass MV, Trent MS. 2020. Restoring balance to the outer membrane: YejM's role in LPS regulation. *mBio* 11:e02624-20. <https://doi.org/10.1128/mBio.02624-20>
22. Sorensen PG, Lutkenhaus J, Young K, Eveland SS, Anderson MS, Raetz CRH. 1996. Regulation OF UDP-3-O-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase in *Escherichia coli*. The second enzymatic step of lipid A biosynthesis. *J Biol Chem* 271:25898–25905. <https://doi.org/10.1074/jbc.271.42.25898>
23. Ogura T, Inoue K, Tatsuta T, Suzuki T, Karata K, Young K, Su LH, Fierke CA, Jackman JE, Raetz CR, Coleman J, Tomoyasu T, Matsuzawa H. 1999. Balanced biosynthesis of major membrane components through regulated degradation of the committed enzyme of lipid A biosynthesis by the AAA protease FtsH (HflB) in *Escherichia coli*. *Mol Microbiol* 31:833–844. <https://doi.org/10.1046/j.1365-2958.1999.01221.x>
24. Price AC, Choi K-H, Heath RJ, Li Z, White SW, Rock CO. 2001. Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin: structure and mechanism. *J Biol Chem* 276:6551–6559. <https://doi.org/10.1074/jbc.M007101200>
25. Noga MJ, Cerri M, Imholz N, Tulinski P, Şahin E, Bokinsky G. 2016. Mass-spectrometry-based quantification of protein-bound fatty acid synthesis intermediates from *Escherichia coli*. *J Proteome Res* 15:3617–3623. <https://doi.org/10.1021/acs.jproteome.6b00405>
26. Lehninger AL. 1946. The synthesis and properties of the acyl phosphates of some higher fatty acids. *J Biol Chem* 162:333–342. [https://doi.org/10.1016/S0021-9258\(17\)41438-4](https://doi.org/10.1016/S0021-9258(17)41438-4)
27. Radka CD, Rock CO. 2022. Mining fatty acid biosynthesis for new antimicrobials. *Annu Rev Microbiol* 76:281–304. <https://doi.org/10.1146/annurev-micro-041320-110408>
28. Cronan JE Jr, Subrahmanyam S. 1998. FadR, transcriptional co-ordination of metabolic expediency. *Mol Microbiol* 29:937–943. <https://doi.org/10.1046/j.1365-2958.1998.00917.x>
29. Vadia S, Tse JL, Lucena R, Yang Z, Kellogg DR, Wang JD, Levin PA. 2017. Fatty acid availability sets cell envelope capacity and dictates microbial cell size. *Curr Biol* 27:1757–1767. <https://doi.org/10.1016/j.cub.2017.05.076>
30. Rock CO, Cronan JE. 1996. *Escherichia coli* as a model for the regulation of dissociable (type II) fatty acid biosynthesis. *Biochim et Biophys Acta (BBA) - Lipids Lipid Metab* 1302:1–16. [https://doi.org/10.1016/0005-2760\(96\)00056-2](https://doi.org/10.1016/0005-2760(96)00056-2)
31. Yao J, Rock CO. 2015. How bacterial pathogens eat host lipids: implications for the development of fatty acid synthesis therapeutics. *J Biol Chem* 290:5940–5946. <https://doi.org/10.1074/jbc.R114.636241>
32. Li Z, Tang Y, Wu Y, Zhao S, Bao J, Luo Y, Li D. 2017. Structural insights into the committed step of bacterial phospholipid biosynthesis. *Nat Commun* 8:1691. <https://doi.org/10.1038/s41467-017-01821-9>
33. Heath RJ, Rock CO. 1999. A missense mutation accounts for the defect in the glycerol-3-phosphate acyltransferase expressed in the plsB26 mutant. *J Bacteriol* 181:1944–1946. <https://doi.org/10.1128/JB.181.6.1944-1946.1999>
34. Bell RM. 1974. Mutants of *Escherichia coli* defective in membrane phospholipid synthesis: macromolecular synthesis in an sn-glycerol 3-phosphate acyltransferase Km mutant. *J Bacteriol* 117:1065–1076. <https://doi.org/10.1128/jb.117.3.1065-1076.1974>
35. Oh WS. 1992. Characterization of an operon containing a ribosomal protein gene and lipid biosynthetic genes in *Escherichia coli* K-12. *V Tech*
36. Larson TJ, Ludtke DN, Bell RM. 1984. Sn-Glycerol-3-phosphate auxotrophy of plsB strains of *Escherichia coli*: evidence that a second mutation, plsX, is required. *J Bacteriol* 160:711–717. <https://doi.org/10.1128/jb.160.2.711-717.1984>
37. Parsons JB, Frank MW, Subramanian C, Saenkham P, Rock CO. 2011. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. *Proc Natl Acad Sci U S A* 108:15378–15383. <https://doi.org/10.1073/pnas.1109208108>
38. Clairfeuille T, Buchholz KR, Li Q, Verschuere E, Liu P, Sangaraju D, Park S, Noland CL, Storek KM, Nickerson NN, et al. 2020. Structure of the essential inner membrane lipopolysaccharide–PbgA complex. *Nature* 584:479–483. <https://doi.org/10.1038/s41586-020-2597-x>
39. Möller A-M, Brückner S, Tilg L-J, Kutscher B, Nowaczyk MM, Narberhaus F. 2023. LapB (YciM) orchestrates protein-protein interactions at the interface of lipopolysaccharide and phospholipid biosynthesis. *Mol Microbiol* 119:29–43. <https://doi.org/10.1111/mmi.15005>
40. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol Syst Biol* 2:2006.0008. <https://doi.org/10.1038/msb4100050>
41. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci USA* 97:6640–6645. <https://doi.org/10.1073/pnas.120163297>
42. VanDrisse CM, Escalante-Semerena JC. 2016. New high-cloning-efficiency vectors for complementation studies and recombinant protein overproduction in *Escherichia coli* and *Salmonella enterica*. *Plasmid* 86:1–6. <https://doi.org/10.1016/j.plasmid.2016.05.001>
43. Purcell AB, Simpson BW, Trent MS. 2023. Impact of the cAMP-cAMP receptor protein regulatory complex on lipopolysaccharide modifications and polymyxin B resistance in *Escherichia coli*. *J Bacteriol* 205:e0006723. <https://doi.org/10.1128/jb.00067-23>
44. Simpson BW, Nieckarz M, Pinedo V, McLean AB, Cava F, Trent MS. 2021. *Acinetobacter baumannii* can survive with an outer membrane lacking lipooligosaccharide due to structural support from elongasome peptidoglycan synthesis. *mBio* 12:e0309921. <https://doi.org/10.1128/mBio.03099-21>